fintech / news / / The Manila Times
Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US.
Novo Nordisk's Q1 2026 sales were boosted by a $4.2 billion 340B provision reversal in the US.
KEY POINTS
- Excluding the 340B reversal, adjusted US sales dropped 11% due to lower realised prices.
- Wegovy pill, launched January 2026 in the US, achieved over 2 million prescriptions by mid-April.
- FDA approved injectable Wegovy HD, delivering 20.7% mean weight loss in the STEP UP trial.
- FDA also approved Awiqli, the first-ever once-weekly basal insulin for type 2 diabetes.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →